Actualités et vidéos - AURIS MEDICAL HOLDING

Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com . The new website features a streamlined and modern design and also reflects the Company’s recently announced strategic repositioning. “We are proud to present our projects and...

Bentrio™ formulation well tolerated in vitro on human nasal epithelium Up to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controls Viral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced...

Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platform Company to launch development program under project code AM-401 with aim of IND submission in late 2022 Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven...

Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online...

Treatment with OligoPhore TM siRNA stops aggressive ATLL tumor growth to near zero Significant reduction in tumor size, spleen size and peripheral blood lymphocyte counts Results add to extensive body of evidence for effective OligoPhore TM enabled delivery of nucleic acids to extrahepatic tissues Hamilton, Bermuda, June 21, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...

Entering field of RNA therapeutics through acquisition of Trasir Therapeutics, Inc. Trasir’s innovative peptide-based OligoPhore TM platform designed to enable extrahepatic delivery of oligonucleotides Trasir’s founder, Dr. Samuel Wickline, joining leadership team as Chief Scientific Officer Strategic repositioning around RNA therapeutics and plans for spin-off or divestiture of existing programs in medium term Extraordinary general meeting of shareholders to vote on change of Company’s...

Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, today announced that its affiliate Altamira Medica Ltd. has started preparations for the conduct of a study with its Bentrio TM nasal spray for protection against airborne viruses and allergens in India. The study will seek to evaluate the efficacy of Bentrio TM in the...

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage...

Meeting essential requirements for marketing Bentrio TM in Europe under CE mark On track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced that it has successfully completed the conformity...

Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it has reached the midpoint for enrollment in Part B of its Phase 2 proof-of-concept trial of AM-125 (intranasal betahistine) in the treatment of acute peripheral vertigo. In Part B of the TRAVERS trial, the Company will enroll 72...

...

Bentrio TM meets primary efficacy endpoint in clinical evaluation in allergic rhinitis Clinically relevant and significant reduction in nasal symptoms Superior efficacy ratings by patients and clinicians Pre-submission meeting with FDA supports 510(k) regulatory pathway Hamilton, Bermuda, May 7, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS...

Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hours Preliminary preclinical data suggest therapeutic utility post SARS-CoV-2 infection Product launch under Bentrio TM brand in selected European countries towards end of Q2 2021 Hamilton, Bermuda, April 13, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Hamilton, Bermuda, April 8, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it will provide a business update on its AM-301 program for protection against airborne viruses and allergens on Tuesday, April 13, 2021. Following the announcement, Auris Medical's management team will host a live conference call and...

Clinical evaluation of AM-301 nasal spray in allergen protection progressing Launch of AM-301 expected in selected markets towards the end of second quarter 2021 Phase 2 trial with AM-125 in acute vertigo expected to complete enrollment in third quarter 2021 Equity and cash position significantly strengthened Strategy review ongoing Hamilton, Bermuda, March 31, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important...

Hamilton, Bermuda, March 24, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it will provide a business update and report its financial results for the second half and full year 2020 on Wednesday, March 31, 2021. Following the announcement, Auris Medical's management team will host a live conference call and...

Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced with its affiliate Altamira Medica AG the initiation of a clinical investigation of AM-301 in allergic rhinitis. The clinical investigation is an open-label randomized cross-over study that will enroll 36 patients with allergic rhinitis to...

Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises AM-301 program progressing towards clinical and regulatory milestones Strategy review ongoing Hamilton, Bermuda, December 15, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today provided a business update related to the Company’s...

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage...

Hamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 2,000,000 common shares, par value CHF 0.01 per share, at an offering price of $4.00 per share,...